Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 792-798

  Chen, Ying ^a   Guo, Qingqu ^a   Zhang, Bo ^a   Kang, Muxing ^a   Xie, Qiuping ^a   Wu, Yulian ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis signal regulating kinase 1; Bufalin; c Jun N terminal protein kinase; Gemcitabine; Pancreatic cancer

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; BUFALIN; GEMCITABINE;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; RANDOMIZED CONTROLLED TRIAL;

EID: 84864646118     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.783     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Shah A N, Summy J M, Zhang J, Park SI, Parikh N U and Gallick GE: Development and characterization of gemcitabineresistant pancreatic tumor cells. Ann Surg Oncol 14: 3629-3637, 2007.
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003.
4. Riall TS, Nealon WH, Goodwin JS, et al: Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg 10: 1212-1223; discussion 1223-1214, 2006.
5. Pearce HL and Alice Miller M: The evolution of cancer research and drug discovery at Lilly Research Laboratories. Adv Enzyme Regul 45: 229-255, 2005.
6. Shen Y, Cai M, Xia W, et al: FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett 254: 288-297, 2007.
7. Lee SH, Ryu JK, Lee KY, et al: Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett 259: 39-49, 2008.
8. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
9. Kimura K, Sawada T, Komatsu M, et al: Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 12: 4925-4932, 2006.
10. Watabe M, Kawazoe N, Masuda Y, Nakajo S and Nakaya K: Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res 57: 3097-3100, 1997.
11. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med 21: 637-643, 2008.
12. Yu CH, Kan SF, Pu HF, Jea Chien E and Wang PS: Apoptotic signaling in bufalin-and cinobufagi n-treated and rogen-dependent and-independent human prostate cancer cells. Cancer Sci 99: 2467-2476, 2008.
13. Nasu K, Nishida M, Ueda T, et al: Bufalin induces apoptosis and the G0/G1 cell cycle arrest of endometriotic stromal cells: a promising agent for the treatment of endometriosis. Mol Hum Reprod 11: 817-823, 2005.
14. Kuo CT, Chen BC, Yu CC, et al: Apoptosis signal-regulating kinase 1 mediates denbinobin-induced apoptosis in human lung adenocarcinoma cells. J Biomed Sci 16: 43, 2009.
15. Schoner W and Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 293: C509-536, 2007.
16. Amano Y, Cho Y, Matsunawa M, Komiyama K and Makishima M: Increased nuclear expression and transactivation of vitamin D receptor by the cardiotonic steroid bufalin in human myeloid leukemia cells. J Steroid Biochem Mol Biol 114: 144-151, 2009.
17. Tang ZY, Wu Y L, Gao SL and Shen H W: Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. J Surg Res 145: 111-123, 2008.
18. Guo Q, Chen Y, Zhang B, Kang M, Xie Q and Wu Y: Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem Pharmacol 77: 1674-1683, 2009.
19. Kornmann M, Beger HG and Link KH: Chemosensitivity testing and test-directed chemotherapy in human pancreatic cancer. Recent Results Cancer Res 161: 180-195, 2003.
20. Zalatnai A and Molnar J: Review. Molecular background of chemoresistance in pancreatic cancer. In Vivo 21: 339-347, 2007.
21. Mimeault M, Hauke R and Batra SK: Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83: 673-691, 2008.
22. Sun L, Chen T, Wang X, Chen Y and Wei X: Bufalin induces reactive oxygen species dependent ba x t ra nslocation a nd apoptosis in ASTC-a-1 cells. Evid Based Complement Alternat Med 2009.
23. Xie CM, Chan WY, Yu S, Zhao J and Cheng CH: Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic Biol Med 51: 1365-1375, 2011.
24. Okamoto K, Ocker M, Neureiter D, et al: bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 11: 349-361, 2007.
25. Kurosawa M, Numazawa S, Tani Y and Yoshida T: ER K signaling mediates the induction of inflammatory cytokines by bufalin in human monocytic cells. Am J Physiol Cell Physiol 278: C500-508, 2000.
26. Kawazoe N, Watabe M, Masuda Y, Nakajo S and Nakaya K: Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene 18: 2413-2421, 1999.
27. Kurosawa M, Tani Y, Nishimura S, Numazawa S and Yoshida T: Distinct PKC isozymes regulate bufalin-induced differentiation and apoptosis in human monocytic cells. Am J Physiol Cell Physiol 280: C459-C464, 2001.
28. Hatai T, Matsuzawa A, Inoshita S, et al: Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation. J Biol Chem 275: 26576-26581, 2000.
29. Ichijo H, Nishida E, Irie K, et al: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275: 90-94, 1997.
30. Numazawa S, Shinoki MA, Ito H, Yoshida T and Kuroiwa Y: Involvement of Na+,K(+)-ATPase inhibition in K562 cell differentiation induced by bufalin. J Cell Physiol 160: 113-120, 1994.
31. Jing Y, Watabe M, Hashimoto S, Nakajo S and Nakaya K: Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells. Anticancer Res 14: 1193-1198, 1994.
32. Masuda Y, Kawazoe N, Nakajo S, Yoshida T, Kuroiwa Y and Nakaya K: Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk Res 19: 549-556, 1995.
33. Su F, Li H, Yan C, Jia B, Zhang Y and Chen X: Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells. J Cancer Res Clin Oncol 135: 1655-1663, 2009.
34. Yu CC, Hsu MJ, Kuo ML, et al: Thrombin-induced connective tissue growth factor expression in human lung fibroblasts re qu i res t he ASK1/J N K /A P-1 pat hway. J I m mu nol 182: 7916-7927, 2009.
35. Yamamoto K, Ichijo H and Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19: 8469-8478, 1999.